- Home
- PROK vs RZLT Comparison
PROK vs RZLT Comparison
Compare PROK & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- RZLT
- Stock Information
- Founded
- PROK 2015
- RZLT 2010
- Country
- PROK United States
- RZLT United States
- Employees
- PROK N/A
- RZLT N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- RZLT Health Care
- Exchange
- PROK Nasdaq
- RZLT Nasdaq
- Market Cap
- PROK 384.2M
- RZLT 361.3M
- IPO Year
- PROK N/A
- RZLT N/A
- Fundamental
- Price
- PROK $2.35
- RZLT $6.47
- Analyst Decision
- PROK Buy
- RZLT Strong Buy
- Analyst Count
- PROK 5
- RZLT 5
- Target Price
- PROK $6.25
- RZLT $12.50
- AVG Volume (30 Days)
- PROK 3.3M
- RZLT 850.8K
- Earning Date
- PROK 08-12-2025
- RZLT 09-18-2025
- Dividend Yield
- PROK N/A
- RZLT N/A
- EPS Growth
- PROK N/A
- RZLT N/A
- EPS
- PROK N/A
- RZLT N/A
- Revenue
- PROK $527,000.00
- RZLT N/A
- Revenue This Year
- PROK $105.79
- RZLT N/A
- Revenue Next Year
- PROK N/A
- RZLT N/A
- P/E Ratio
- PROK N/A
- RZLT N/A
- Revenue Growth
- PROK N/A
- RZLT N/A
- 52 Week Low
- PROK $0.46
- RZLT $2.22
- 52 Week High
- PROK $7.13
- RZLT $6.65
- Technical
- Relative Strength Index (RSI)
- PROK 43.77
- RZLT 68.65
- Support Level
- PROK $2.16
- RZLT $5.52
- Resistance Level
- PROK $2.46
- RZLT $6.61
- Average True Range (ATR)
- PROK 0.34
- RZLT 0.30
- MACD
- PROK -0.16
- RZLT 0.00
- Stochastic Oscillator
- PROK 7.14
- RZLT 80.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.